

## A. Audited Financial Results for the Quarter and Year ended 31st March 2013

(Rs. in Lacs)

Sr. No.	Particulars	Audited (Refer Note-2)	Unaudited		Audited	Audited
		Quarter ended			Year ended	Year Ended
		3 months ended 31.03.13	Previous 3 months ended in the current year 31.12.12	Corresponding 3 months ended in the previous year 31.03.12	Current accounting year ended 31.03.13	Previous accounting year ended 31.03.12
1	Sales/Income from operation(Net of Excise duty)	4590.55	3548.74	4003.68	12525.87	15318.19
2	Other Operating Income	26.67	0.00	54.22	104.32	60.43
3	Total Net Income from Operation	4617.22	3548.74	4057.90	12630.19	15378.62
4	Expenditure					
	(a) Increase / decrease in stock in trade & work in progress	1307.55	(350.21)	(1186.64)	2005.28	(1576.15)
	(b) Consumption of raw materials	2711.32	2981.79	4781.49	8104.06	12444.85
	(c) Employees Cost	261.41	250.43	182.82	946.32	914.77
	(d) Depreciation	100.62	97.78	98.51	393.97	373.64
	(e) Other expenditure	437.34	550.40	117.94	1911.19	2126.26
	(f) Total	4818.24	3530.19	3994.12	13360.82	14283.37
5	Profit(+)/Loss(-) from operations before Other income, Finance cost and Exceptional Items(3-4)	(201.02)	18.55	63.78	(730.63)	1095.25
6	Other income	50.86	0.12	28.98	52.96	34.97
7	Profit (+) / Loss (-) from ordinary activities before Finance Cost & Exceptional Items(5+6)	(150.16)	18.67	92.76	(677.67)	1130.22
8	Finance Cost	253.20	268.67	303.97	1002.24	1016.43
9	Profit(+)/Loss(-) from ordinary activities after Finance cost & Exceptional Items(7-8)	(403.36)	(250.00)	(211.21)	(1679.91)	113.79
10	Exceptional Items	0.00	0.00	0.00	0.00	0.00
11	Profit(+)/Loss(-) before Tax (9-10)	(403.36)	(250.00)	(211.21)	(1679.91)	113.79
12	Tax Expenses(incl Deferred Tax)	(499.98)	0.00	(18.58)	(499.98)	50.42
13	Net Profit(+)/Loss(-) after Tax (11-12)	96.62	(250.00)	(192.63)	(1179.93)	63.37
14	Extraordinary Items	0.00	0.00	0.00	0.00	0.00
15	Net Profit(+)/Loss(-) for the period(13-14)	96.62	(250.00)	(192.63)	(1179.93)	63.37
16	Paid up Equity Share Capital (face value Rs.10/-each)	1317.82	1317.82	1317.82	1317.82	1317.82
12	Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year.				1308.40	2488.33
13	Earning per share (EPS)					
	(a) Basic and diluted EPS before extraordinary items for the period, for the year to date and for the previous year (not to be annualized)	0.73	(1.90)	(1.46)	(8.96)	0.48
	(b) Basic and diluted EPS after extraordinary items for the period, for the year to date and for the previous year (not to be annualized)	0.73	(1.90)	(1.46)	(8.96)	0.48
14	Non Promoters Shareholding					
	- Number of shares	7548453	7548453	7518093	7548453	7518093
	- Percentage of shareholding	57.28	57.28	57.05	57.28	57.05
15	Promoters and Promoter group Shareholding					
	a) Pledged/ Encumbered					
	Number of Shares	5448708	5448708	1441095	5448708	1441095
	Percentage of Shares (as a % of the total shareholding of promoter & promoter group)	96.78	96.78	25.46	96.78	25.46
	Percentage of Shares (as a % of the total share capital of the company)	41.35	41.35	10.94	41.35	10.94
	b) Non-encumbered					
	Number of Shares	181087	181087	4219060	181087	4219060
	Percentage of Shares (as a % of the total shareholding of promoter & promoter group)	3.22	3.22	74.54	3.22	74.54
	Percentage of Shares (as a % of the total share capital of the company)	1.37	1.37	32.01	1.37	32.01

## Notes:

- The above results have been reviewed by the Audit Committee and thereafter, were taken on record by the Board of Directors of the Company at their meeting held on 23rd, May 2013
- The results for the quarter ended March 31, 2013 are derived figures arrived at by subtracting the results for the nine months ended on December 31, 2012 from the audited results for the year ended March 31, 2013.
- As the Company's business activity falls within a single primary business segment viz "Manufacturing of Bulk drugs" the disclosure requirement of Accounting Standard(AS-17)"Segment Reporting" is not applicable.
- During the Quarter & Year ended 31st March 2013, 0 investor complaint were received, all of which have been attended by the company. No complaints were pending at the beginning or at the end of the quarter.
- Previous year figure are regrouped wherever necessary.

Place: Mumbai  
Date: 23.05.2013

On behalf of Board of Directors  
For Mahalaxmi Drugs & Organics Ltd

Director  
(Shri Govardhan M. Dhoot)